Palliative Care — MCQs

Q: A 70-year-old man with advanced pancreatic cancer on sustained-release morphine 60 mg BD develops breakthrough pain 3-4 times daily. His pain is otherwise well controlled. What should be the dose of immediate-release morphine for breakthrough pain?

12 mg. ***12 mg*** - The standard dose for **breakthrough pain** is calculated as **one-sixth (approx 16%) or 10%** of the **total daily dose** (TDD) of the regular opioid. - Since the patient takes 60 mg twice daily, the **TDD is 120 mg**; 10% of 120 mg is **12 mg**, providing a safe and effective immediate-release dose [1]. *6 mg* - This dose represents only **5%** of the TDD, which is typically insufficient to manage moderate-to-severe **breakthrough pain**. - Using a dose this low may lead to **inadequate analgesia** and multiple repeat doses, which is not clinically optimal [1]. *20 mg* - This dose exceeds the standard **10-16% recommendation** for breakthrough medication in a patient whose pain is otherwise and normally **well controlled**. - High breakthrough doses relative to the TDD increase the risk of **opioid toxicity**, such as excessive sedation or **respiratory depression**. *30 mg* - This is **25%** of the daily dose, which is significantly higher than the recommended safety margin for **palliative care** breakthrough protocols [1]. - Such a high dose would typically only be considered if the **background pain** was also poorly controlled and the oral dose was being titrated upward.

Q: A 58-year-old woman with terminal breast cancer presents with severe nausea and vomiting due to hypercalcemia and gastroparesis. Which antiemetic would be most appropriate?

Haloperidol. ***Haloperidol*** - **Haloperidol** is highly effective for nausea caused by **metabolic derangements** such as **hypercalcemia** because it acts as a potent **D2 receptor antagonist** in the **chemoreceptor trigger zone (CTZ)** [1]. - It is a first-line agent in **palliative care** for chemical causes of vomiting and is generally preferred when multiple systemic factors are at play. *Cyclizine* - This is an **antihistamine** that primarily targets the **vestibular system** and the vomiting center, making it more suitable for **motion sickness** or raised intracranial pressure. - It lacks the specific action on the **CTZ** required to effectively manage nausea secondary to **hypercalcemia** [1]. *Ondansetron* - This **5-HT3 receptor antagonist** is primarily indicated for **chemotherapy-induced** or postoperative nausea and vomiting. - It is frequently associated with **constipation**, which can worsen the gastrointestinal distress already present in patients with **hypercalcemia** and gastroparesis. *Metoclopramide* - While it has **prokinetic** properties, its efficacy is limited in the context of **hypercalcemia-induced** nausea which is mediated chemically via the brain rather than just mechanically. - Although useful for mild **gastroparesis**, it is less effective than central dopamine antagonists for the systemic metabolic triggers seen in terminal malignancy cases.

Q: A 65-year-old man with metastatic lung cancer is receiving oral morphine 30 mg every 4 hours for pain control. He develops severe dysphagia and cannot take oral medications. What is the appropriate 24-hour subcutaneous morphine dose?

90 mg. ***90 mg*** - The patient's total daily dose of **oral morphine** is 180 mg (30 mg every 4 hours, which is 6 doses per day) [1]. - When converting from **oral to subcutaneous morphine**, a **conversion ratio of 2:1** is used due to the higher bioavailability of parenteral administration; thus, 180 mg oral / 2 = 90 mg subcutaneous [1]. *60 mg* - This dose would represent a **3:1 conversion ratio**, which is more commonly used for converting oral morphine to **intravenous/subcutaneous diamorphine** in some guidelines, not morphine to morphine. - Using this dose would result in **undermedication** and inadequate pain control for this patient with metastatic cancer. *180 mg* - This is a **1:1 conversion ratio**, which ignores the **first-pass metabolism** that oral morphine undergoes. - Administering the same dose subcutaneously would likely lead to **opioid toxicity**, characterized by respiratory depression and sedation, because parenteral morphine is much more potent [1]. *45 mg* - This dose represents a **4:1 conversion ratio**, which is significantly lower than the standard clinical recommendation for **opioid rotation** from oral to SC morphine [1]. - Such a low dose would likely cause a **pain crisis** or withdrawal symptoms due to insufficient analgesia for the patient's existing needs.

Q: Why is dexamethasone preferred over other corticosteroids for symptom management in terminal cancer patients?

It has the least mineralocorticoid activity. ***It has the least mineralocorticoid activity*** - **Dexamethasone** possesses negligible **mineralocorticoid activity**, which significantly reduces the risk of **fluid retention**, edema, and hypertension in fragile terminal patients. - Its high **glucocorticoid potency** and long **biological half-life** make it highly effective for managing **cerebral edema**, nausea, and cancer-related pain with once-daily dosing [1]. *It has maximum immunosuppressive effect* - While it is a potent immunosuppressant, this is generally a **side effect** or a secondary goal rather than the primary reason for its preference in **symptom palliation**. - Prednisone or other steroids could provide significant immunosuppression, but they carry a higher risk of **fluid-related complications**. *It has shorter half-life allowing better control* - This is incorrect; Dexamethasone has a **long half-life** (36-72 hours), which is preferred because it allows for **infrequent dosing** and maintains stable plasma levels. - **Hydrocortisone** has a shorter half-life but requires multiple doses daily, which increases the **treatment burden** for palliative patients. *It does not cross blood-brain barrier* - Dexamethasone **readily crosses** the **blood-brain barrier**, which is exactly why it is the drug of choice for treating **peritumoral brain edema**. - Its ability to penetrate the **central nervous system** helps alleviate symptoms like headaches and neurological deficits caused by **brain metastases**.

Q: According to WHO analgesic ladder for cancer pain management, which medication should be added at Step 2?

Weak opioids. ***Weak opioids*** - Step 2 of the **WHO analgesic ladder** is indicated for **mild to moderate pain** and involves the addition of **weak opioids** such as **codeine** or **tramadol** to non-opioid medications [1]. - These are often administered in combination with **paracetamol** or **NSAIDs** to enhance analgesic efficacy through different mechanisms of action [1]. *Ketamine* - **Ketamine** is an **NMDA receptor antagonist** used as an **adjuvant** for complex or refractory pain, but it is not a standard component of the three basic steps. - It is typically reserved for specialized pain management rather than being a routine step 2 medication. *Strong opioids* - **Strong opioids**, such as **morphine**, **fentanyl**, or **oxycodone**, are the hallmark of **Step 3** of the ladder [1]. - Step 3 is reserved for **moderate to severe pain** or when pain is not controlled by weak opioids [1]. *NSAIDs alone* - Using **NSAIDs alone** constitutes **Step 1** of the WHO ladder, which is intended for **mild pain** [1]. - In Step 2, non-opioids like NSAIDs are continued as **background therapy**, but the defining addition is the opioid component.

Q: Which of the following is the most appropriate opioid for initiation of pain management in a patient with moderate to severe cancer pain who is opioid-naive?

Morphine immediate release. ***Morphine immediate release*** - **Morphine immediate release (IR)** is the gold standard for initiating opioid therapy in **opioid-naive** patients because it allows for rapid **dose titration** to achieve effective analgesia. [1] - It has a predictable **pharmacokinetic profile**, making it safer and easier to adjust based on the patient's individual pain requirements and response. [1] *Fentanyl transdermal patch* - **Fentanyl patches** are contraindicated in **opioid-naive** patients due to the high risk of **respiratory depression** from a slow-onset, potent dose. [1] - These patches have a long **half-life** and take 12-24 hours to reach steady-state, making them unsuitable for acute dose escalation. [1] *Buprenorphine sublingual* - **Buprenorphine** is a **partial mu-opioid agonist** and has a "ceiling effect" for analgesia, which may limit its utility in severe escalating cancer pain. - While useful in certain settings, it is generally not the first choice for **initial titration** when compared to pure agonists like morphine. *Methadone* - **Methadone** has a very long and **unpredictable half-life**, which increases the danger of accumulation and **toxicity** in patients not already accustomed to opioids. [1] - It requires sophisticated titration due to its complex **pharmacokinetics** and potential to cause **QT interval prolongation**.

Palliative Care Indian Medical PG Practice Questions and MCQs

Question 1: A 68-year-old man with terminal lung cancer develops confusion, myoclonus, and hallucinations after being on high-dose morphine (240 mg/day oral) for 2 weeks. His renal function shows creatinine 2.8 mg/dL. What is the most appropriate management considering the pathophysiology?

A. Continue morphine but add naloxone infusion
B. Add haloperidol for delirium and continue morphine
C. Switch to fentanyl as it has no active metabolites and dose adjust for renal function (Correct Answer)
D. Stop all opioids and use only adjuvant analgesics

Explanation: ***Switch to fentanyl as it has no active metabolites and dose adjust for renal function*** - The patient is experiencing **opioid-induced neurotoxicity (OIN)** due to the accumulation of morphine metabolites, specifically **Morphine-3-glucuronide (M3G)** and **Morphine-6-glucuronide (M6G)**, which are cleared renally. - **Fentanyl** is the preferred opioid in renal impairment because it has no clinically significant active metabolites and does not undergo significant renal excretion [1]. *Continue morphine but add naloxone infusion* - Adding **naloxone** would reverse the analgesic effects and likely precipitate an acute **withdrawal syndrome** or uncontrolled cancer pain. - This does not address the underlying cause, which is the accumulation of **neuroexcitatory metabolites** in the setting of renal failure. *Add haloperidol for delirium and continue morphine* - **Haloperidol** may mask the symptoms of delirium but does not stop the progression of **myoclonus** or neurotoxicity caused by toxic metabolites. - Continuing morphine in a patient with a **creatinine of 2.8 mg/dL** will lead to further metabolite accumulation and potential seizures. *Stop all opioids and use only adjuvant analgesics* - Abruptly stopping opioids in a patient on a high dose (240 mg/day) will lead to severe **withdrawal** and a massive **pain crisis**. - Terminal lung cancer pain requires effective opioid management; switching to a safer agent (opioid rotation) is the standard of care rather than complete discontinuation [1].

Question 2: A 62-year-old woman with advanced ovarian cancer has been on oral morphine 90 mg BD for 3 months. She now reports reduced pain relief despite increasing doses, but experiences severe pain at specific sites of bone metastases. What is the best management strategy?

A. Add ketamine infusion for opioid resistance
B. Switch to fentanyl patch and continue dose escalation
C. Add gabapentin and consider palliative radiotherapy to metastatic sites (Correct Answer)
D. Rotate to hydromorphone at equianalgesic dose

Explanation: ***Add gabapentin and consider palliative radiotherapy to metastatic sites*** - Bone metastases often cause **neuropathic pain** and inflammatory response; adding a **gabapentinoid** treats the nerve-related component that opioids may not fully cover [1]. - **Palliative radiotherapy** is highly effective for localized bone pain, often allowing for **reduced opioid requirements** and improved quality of life. *Add ketamine infusion for opioid resistance* - While **ketamine** is an NMDA antagonist used for refractory pain, it is generally reserved for specialists when common adjuncts and localized treatments fail. - It is a more invasive and complex intervention compared to **radiotherapy** and oral adjuvants like **gabapentin** for focal bone pain. *Switch to fentanyl patch and continue dose escalation* - Increasing the dose of a different opioid (dose escalation) is unlikely to resolve **opioid-insensitive** bone pain and may increase the risk of **opioid-induced hyperalgesia** [2]. - Transdermal **fentanyl** is more suitable for stable pain control and does not address the localized, metastatic nature of the patient's pain [1]. *Rotate to hydromorphone at equianalgesic dose* - **Opioid rotation** to hydromorphone is helpful if the patient is experiencing side effects, but it does not address the underlying pathology of **bone metastases** [1]. - Rotation alone does not provide the specific **neuropathic** or **anti-tumor** benefits offered by the combination of gabapentin and radiotherapy.

Question 3: A 55-year-old man with terminal esophageal cancer develops respiratory secretions causing death rattle. Despite positioning and suctioning, the symptom persists. Which medication would be most appropriate and why?

A. Morphine - reduces respiratory drive and secretions
B. Hyoscine butylbromide - antimuscarinic action reduces secretions without sedation (Correct Answer)
C. Midazolam - sedates patient reducing awareness of secretions
D. Furosemide - reduces fluid overload causing secretions

Explanation: Hyoscine butylbromide - antimuscarinic action reduces secretions without sedation - **Hyoscine butylbromide** is the preferred medication for the **death rattle** because its **antimuscarinic properties** effectively dry up salivary and bronchial secretions. - Unlike hyoscine hydrobromide, it does not cross the **blood-brain barrier**, meaning it reduces secretions with minimal risk of **sedation** or **delirium**. *Morphine - reduces respiratory drive and secretions* - While **morphine** is excellent for managing **dyspnea** and pain at the end of life, it does not possess **antisecretory** properties to manage a death rattle [1]. - Overuse of opioids for secretions can lead to unnecessary **respiratory depression** or decreased level of consciousness without fixing the noisy breathing. *Midazolam - sedates patient reducing awareness of secretions* - **Midazolam** is a benzodiazepine used for **terminal agitation** or anxiety but does not affect the production of **respiratory secretions**. - Although it might reduce patient awareness, it does not address the **audible noise** which is often distressing for the family members observing the patient [2]. *Furosemide - reduces fluid overload causing secretions* - **Furosemide** is indicated for **pulmonary edema** caused by congestive heart failure, not for the terminal accumulation of oropharyngeal secretions. - Using diuretics in a terminal patient with a death rattle is generally **ineffective** as the noise is caused by pooled saliva rather than **systemic fluid overload**.

Question 4: A 70-year-old man with advanced pancreatic cancer on sustained-release morphine 60 mg BD develops breakthrough pain 3-4 times daily. His pain is otherwise well controlled. What should be the dose of immediate-release morphine for breakthrough pain?

A. 6 mg
B. 12 mg (Correct Answer)
C. 20 mg
D. 30 mg

Explanation: ***12 mg*** - The standard dose for **breakthrough pain** is calculated as **one-sixth (approx 16%) or 10%** of the **total daily dose** (TDD) of the regular opioid. - Since the patient takes 60 mg twice daily, the **TDD is 120 mg**; 10% of 120 mg is **12 mg**, providing a safe and effective immediate-release dose [1]. *6 mg* - This dose represents only **5%** of the TDD, which is typically insufficient to manage moderate-to-severe **breakthrough pain**. - Using a dose this low may lead to **inadequate analgesia** and multiple repeat doses, which is not clinically optimal [1]. *20 mg* - This dose exceeds the standard **10-16% recommendation** for breakthrough medication in a patient whose pain is otherwise and normally **well controlled**. - High breakthrough doses relative to the TDD increase the risk of **opioid toxicity**, such as excessive sedation or **respiratory depression**. *30 mg* - This is **25%** of the daily dose, which is significantly higher than the recommended safety margin for **palliative care** breakthrough protocols [1]. - Such a high dose would typically only be considered if the **background pain** was also poorly controlled and the oral dose was being titrated upward.

Question 5: A 58-year-old woman with terminal breast cancer presents with severe nausea and vomiting due to hypercalcemia and gastroparesis. Which antiemetic would be most appropriate?

A. Cyclizine
B. Ondansetron
C. Haloperidol (Correct Answer)
D. Metoclopramide

Explanation: ***Haloperidol*** - **Haloperidol** is highly effective for nausea caused by **metabolic derangements** such as **hypercalcemia** because it acts as a potent **D2 receptor antagonist** in the **chemoreceptor trigger zone (CTZ)** [1]. - It is a first-line agent in **palliative care** for chemical causes of vomiting and is generally preferred when multiple systemic factors are at play. *Cyclizine* - This is an **antihistamine** that primarily targets the **vestibular system** and the vomiting center, making it more suitable for **motion sickness** or raised intracranial pressure. - It lacks the specific action on the **CTZ** required to effectively manage nausea secondary to **hypercalcemia** [1]. *Ondansetron* - This **5-HT3 receptor antagonist** is primarily indicated for **chemotherapy-induced** or postoperative nausea and vomiting. - It is frequently associated with **constipation**, which can worsen the gastrointestinal distress already present in patients with **hypercalcemia** and gastroparesis. *Metoclopramide* - While it has **prokinetic** properties, its efficacy is limited in the context of **hypercalcemia-induced** nausea which is mediated chemically via the brain rather than just mechanically. - Although useful for mild **gastroparesis**, it is less effective than central dopamine antagonists for the systemic metabolic triggers seen in terminal malignancy cases.

Question 6: A 65-year-old man with metastatic lung cancer is receiving oral morphine 30 mg every 4 hours for pain control. He develops severe dysphagia and cannot take oral medications. What is the appropriate 24-hour subcutaneous morphine dose?

A. 90 mg (Correct Answer)
B. 60 mg
C. 180 mg
D. 45 mg

Explanation: ***90 mg*** - The patient's total daily dose of **oral morphine** is 180 mg (30 mg every 4 hours, which is 6 doses per day) [1]. - When converting from **oral to subcutaneous morphine**, a **conversion ratio of 2:1** is used due to the higher bioavailability of parenteral administration; thus, 180 mg oral / 2 = 90 mg subcutaneous [1]. *60 mg* - This dose would represent a **3:1 conversion ratio**, which is more commonly used for converting oral morphine to **intravenous/subcutaneous diamorphine** in some guidelines, not morphine to morphine. - Using this dose would result in **undermedication** and inadequate pain control for this patient with metastatic cancer. *180 mg* - This is a **1:1 conversion ratio**, which ignores the **first-pass metabolism** that oral morphine undergoes. - Administering the same dose subcutaneously would likely lead to **opioid toxicity**, characterized by respiratory depression and sedation, because parenteral morphine is much more potent [1]. *45 mg* - This dose represents a **4:1 conversion ratio**, which is significantly lower than the standard clinical recommendation for **opioid rotation** from oral to SC morphine [1]. - Such a low dose would likely cause a **pain crisis** or withdrawal symptoms due to insufficient analgesia for the patient's existing needs.

Question 7: Why is dexamethasone preferred over other corticosteroids for symptom management in terminal cancer patients?

A. It has the least mineralocorticoid activity (Correct Answer)
B. It has maximum immunosuppressive effect
C. It has shorter half-life allowing better control
D. It does not cross blood-brain barrier

Explanation: ***It has the least mineralocorticoid activity*** - **Dexamethasone** possesses negligible **mineralocorticoid activity**, which significantly reduces the risk of **fluid retention**, edema, and hypertension in fragile terminal patients. - Its high **glucocorticoid potency** and long **biological half-life** make it highly effective for managing **cerebral edema**, nausea, and cancer-related pain with once-daily dosing [1]. *It has maximum immunosuppressive effect* - While it is a potent immunosuppressant, this is generally a **side effect** or a secondary goal rather than the primary reason for its preference in **symptom palliation**. - Prednisone or other steroids could provide significant immunosuppression, but they carry a higher risk of **fluid-related complications**. *It has shorter half-life allowing better control* - This is incorrect; Dexamethasone has a **long half-life** (36-72 hours), which is preferred because it allows for **infrequent dosing** and maintains stable plasma levels. - **Hydrocortisone** has a shorter half-life but requires multiple doses daily, which increases the **treatment burden** for palliative patients. *It does not cross blood-brain barrier* - Dexamethasone **readily crosses** the **blood-brain barrier**, which is exactly why it is the drug of choice for treating **peritumoral brain edema**. - Its ability to penetrate the **central nervous system** helps alleviate symptoms like headaches and neurological deficits caused by **brain metastases**.

Question 8: What is the mechanism by which opioids cause constipation in palliative care patients?

A. Inhibition of bile secretion
B. Direct toxic effect on intestinal mucosa
C. Activation of mu receptors in myenteric plexus reducing peristalsis (Correct Answer)
D. Dehydration due to increased renal sodium excretion

Explanation: ***Activation of mu receptors in myenteric plexus reducing peristalsis*** - Opioids bind to **mu-opioid receptors** in the enteric nervous system, specifically the **myenteric plexus**, leading to a significant decrease in **propulsive peristaltic contractions**. [1] - This activation also increases **sphincter tone** and promotes excessive **fluid absorption**, resulting in the hard, dry stools characteristic of **opioid-induced constipation (OIC)**. [1] *Inhibition of bile secretion* - Bile secretion is not the primary target of opioid action in the gut; OIC is driven by **motility** and **secretory** changes rather than malabsorption of fats. - While opioids can cause **sphincter of Oddi dysfunction**, this leads to biliary pain rather than the systemic constipation seen in palliative care. *Direct toxic effect on intestinal mucosa* - Opioids do not cause **structural damage** or toxicity to the **intestinal epithelial lining**; their effects are purely functional and mediated by receptors. - Unlike certain chemotherapeutic agents that cause **mucositis**, opioids leave the mucosa intact while slowing the **transit time**. *Dehydration due to increased renal sodium excretion* - Opioids do not have a primary mechanism of increasing **renal sodium excretion** or causing systemic dehydration via the kidneys. - Although dehydration can worsen constipation, the primary cause in these patients is the local effect of the drug on **intestinal transit** and increased **colonic water reabsorption**.

Question 9: According to WHO analgesic ladder for cancer pain management, which medication should be added at Step 2?

A. Ketamine
B. Strong opioids
C. Weak opioids (Correct Answer)
D. NSAIDs alone

Explanation: ***Weak opioids*** - Step 2 of the **WHO analgesic ladder** is indicated for **mild to moderate pain** and involves the addition of **weak opioids** such as **codeine** or **tramadol** to non-opioid medications [1]. - These are often administered in combination with **paracetamol** or **NSAIDs** to enhance analgesic efficacy through different mechanisms of action [1]. *Ketamine* - **Ketamine** is an **NMDA receptor antagonist** used as an **adjuvant** for complex or refractory pain, but it is not a standard component of the three basic steps. - It is typically reserved for specialized pain management rather than being a routine step 2 medication. *Strong opioids* - **Strong opioids**, such as **morphine**, **fentanyl**, or **oxycodone**, are the hallmark of **Step 3** of the ladder [1]. - Step 3 is reserved for **moderate to severe pain** or when pain is not controlled by weak opioids [1]. *NSAIDs alone* - Using **NSAIDs alone** constitutes **Step 1** of the WHO ladder, which is intended for **mild pain** [1]. - In Step 2, non-opioids like NSAIDs are continued as **background therapy**, but the defining addition is the opioid component.

Question 10: Which of the following is the most appropriate opioid for initiation of pain management in a patient with moderate to severe cancer pain who is opioid-naive?

A. Fentanyl transdermal patch
B. Morphine immediate release (Correct Answer)
C. Buprenorphine sublingual
D. Methadone

Explanation: ***Morphine immediate release*** - **Morphine immediate release (IR)** is the gold standard for initiating opioid therapy in **opioid-naive** patients because it allows for rapid **dose titration** to achieve effective analgesia. [1] - It has a predictable **pharmacokinetic profile**, making it safer and easier to adjust based on the patient's individual pain requirements and response. [1] *Fentanyl transdermal patch* - **Fentanyl patches** are contraindicated in **opioid-naive** patients due to the high risk of **respiratory depression** from a slow-onset, potent dose. [1] - These patches have a long **half-life** and take 12-24 hours to reach steady-state, making them unsuitable for acute dose escalation. [1] *Buprenorphine sublingual* - **Buprenorphine** is a **partial mu-opioid agonist** and has a "ceiling effect" for analgesia, which may limit its utility in severe escalating cancer pain. - While useful in certain settings, it is generally not the first choice for **initial titration** when compared to pure agonists like morphine. *Methadone* - **Methadone** has a very long and **unpredictable half-life**, which increases the danger of accumulation and **toxicity** in patients not already accustomed to opioids. [1] - It requires sophisticated titration due to its complex **pharmacokinetics** and potential to cause **QT interval prolongation**.

Question 11: What is the meaning of 'Hospice'?

A. Euthanasia for cancer patients
B. Association of colostomy patients in U.S.A.
C. A service providing special care for the old and terminally ill patients (Correct Answer)
D. Mercy killing of patients in a coma

Explanation: **Explanation:** **Hospice care** is a specialized philosophy of medical care that focuses on the palliation of a terminally ill patient's pain and symptoms [1], while attending to their emotional and spiritual needs at the end of life [3]. Unlike curative medicine, the goal of hospice is **quality of life** rather than the duration of life. It is typically indicated when a patient has a life expectancy of six months or less and has opted to forego curative treatments [2]. **Analysis of Options:** * **Option C (Correct):** Hospice provides a multidisciplinary approach (involving doctors, nurses, social workers, and counselors) to manage the physical and psychological distress of the elderly and terminally ill [1]. * **Option A & D (Incorrect):** Hospice is strictly against **Euthanasia** or **Mercy Killing**. Hospice care neither hastens nor postpones death; it allows the natural process of dying to occur with dignity and comfort. * **Option B (Incorrect):** This is a distractor. While support groups exist for colostomy patients (like the United Ostomy Associations of America), they are unrelated to the definition of hospice. **High-Yield Clinical Pearls for NEET-PG:** * **Palliative vs. Hospice:** Palliative care can begin at the time of diagnosis and alongside curative treatment [1]. Hospice is a subset of palliative care specifically for the **terminal phase** (end-of-life). * **The "Double Effect":** A key ethical principle in hospice where a clinician administers a medication (like Morphine) to relieve pain [3], even if it may incidentally hasten death, provided the *intent* was solely symptom relief. * **Primary Goal:** Management of "Total Pain" (physical, psychological, social, and spiritual) [1].

Question 12: To control pain in long standing cancer cases, what is the recommended route of administration?

A. Intravenous
B. Subcutaneous
C. Sublingual
D. Oral (Correct Answer)

Explanation: **Explanation:** The management of cancer pain follows the **WHO Analgesic Ladder**, which emphasizes the principle of **"By the Mouth"** as the primary rule of administration [1]. **Why Oral is the Correct Answer:** For long-standing (chronic) cancer pain, the **oral route** is the preferred and recommended method because it is non-invasive, cost-effective, and allows for the most consistent plasma drug levels [1]. It promotes patient autonomy, as it can be easily managed at home without the need for specialized medical equipment or nursing supervision. Sustained-release formulations (e.g., Morphine) provide long-lasting analgesia, which is ideal for chronic pain management [1]. **Analysis of Incorrect Options:** * **Intravenous (IV):** While IV administration has the fastest onset, it is reserved for acute crises, titration in emergencies, or when the patient is unable to swallow. It is impractical for long-term home care due to the risk of infection and the need for venous access. * **Subcutaneous (SC):** This is the preferred alternative if the oral route is unavailable (e.g., vomiting or dysphagia), but it is not the first-line choice for routine long-standing pain. * **Sublingual:** This route is useful for "breakthrough pain" due to rapid absorption, but it is not suitable for baseline control of long-standing pain because many drugs have poor sublingual bioavailability or short durations of action. **High-Yield Clinical Pearls for NEET-PG:** * **WHO Ladder Principles:** 1. By the mouth, 2. By the clock (regular intervals), 3. By the ladder (stepwise potency), 4. For the individual. * **Step 3 Gold Standard:** Oral Morphine remains the drug of choice for severe cancer pain [1]. * **Constipation:** This is the most common persistent side effect of opioids; unlike nausea, tolerance to constipation never develops. Always co-prescribe a stimulant laxative.

Question 13: HOSPICE is related to:

A. Contraception
B. Palliative care of terminally ill (Correct Answer)
C. Screening of tumours
D. Triage in disasters

Explanation: **Explanation:** **Hospice care** is a specialized philosophy of care that focuses on the palliation of a terminally ill patient's pain and symptoms, while attending to their emotional and spiritual needs at the end of life [1]. Unlike standard medical care, the goal of hospice is not to cure the underlying disease but to prioritize **quality of life** and comfort when curative treatment is no longer possible or desired (typically when life expectancy is <6 months) [1]. **Analysis of Options:** * **Option B (Correct):** Hospice is the gold standard for end-of-life care. It involves an interdisciplinary team (doctors, nurses, social workers, and counselors) providing "comfort care" rather than "curative care." * **Option A (Incorrect):** Contraception refers to preventive methods to avoid pregnancy, managed under Reproductive and Child Health (RCH) programs. * **Option C (Incorrect):** Screening of tumors involves secondary prevention (e.g., Pap smears, mammography) to detect cancer in asymptomatic individuals at an early, treatable stage. * **Option D (Incorrect):** Triage is the process of prioritizing patients based on the severity of their condition during mass casualty incidents or disasters to maximize survivors. **High-Yield Clinical Pearls for NEET-PG:** * **Palliative Care vs. Hospice:** Palliative care can begin at the time of diagnosis and alongside curative treatment; Hospice is a specific type of palliative care reserved for the terminal phase of an illness [1]. * **The "Total Pain" Concept:** Introduced by Cicely Saunders (founder of the modern hospice movement), it addresses physical, psychological, social, and spiritual distress. * **Morphine:** The "Gold Standard" drug for managing severe cancer pain and dyspnea in palliative settings. * **Goal:** To ensure a "Dignified Death."

Question 14: A 40-year-old divorced mother of four school-age children is hospitalized with metastatic cancer of the ovary. The nurse finds the patient crying, and she tells the nurse that she does not know what will happen to her children when she dies. What is the most appropriate nursing response?

A. Why don’t we talk about the options you have for the care of your children?
B. Many patients with cancer live for a long time, so there is time to plan for your children. (Correct Answer)
C. For now you need to concentrate on getting well, not worry about your children.
D. Perhaps your ex-husband will take the children when you can’t care for them.

Explanation: ### Explanation **Correct Option: B (Many patients with cancer live for a long time, so there is time to plan for your children.)** In palliative care and oncology nursing, the primary goal when addressing a patient's emotional distress is to provide **realistic hope** while acknowledging their concerns. This response is therapeutic because it validates the patient’s anxiety but offers a perspective that balances the gravity of the diagnosis with the possibility of time [1]. It reduces immediate panic, allowing the patient to transition from a state of acute emotional crisis to a more stable state where constructive planning can eventually occur. Many people wish their doctors to be honest about the situation to allow them time to think ahead, make plans, and address practical issues [1]. **Why the other options are incorrect:** * **Option A:** While practical, this response is premature. The patient is currently in an acute emotional state (crying). Jumping immediately into "logistics" ignores the patient's emotional needs and may feel dismissive of her grief. * **Option C:** This is **non-therapeutic** and patronizing. Telling a patient "not to worry" invalidates their feelings and shuts down communication. It creates a barrier between the patient and the healthcare provider. * **Option D:** This is highly inappropriate as it makes assumptions about the patient's personal relationships and family dynamics. It may inadvertently cause more distress if the relationship with the ex-husband is strained or abusive. --- ### Clinical Pearls for NEET-PG: * **Therapeutic Communication:** Always prioritize **active listening** and **validation** of the patient's feelings before moving to problem-solving [1]. * **SPIKES Protocol:** Remember this mnemonic for breaking bad news: **S**etting, **P**erception, **I**nvitation, **K**nowledge, **E**mpathy, **S**trategy/Summary. * **Palliative Care Goal:** It is not just about end-of-life care; it is about improving the **Quality of Life (QoL)** and addressing physical, psychosocial, and spiritual suffering at any stage of a serious illness [1]. * **High-Yield Fact:** In metastatic ovarian cancer, while the prognosis is often guarded, the introduction of PARP inhibitors and advanced chemotherapy has significantly extended survival, making "time to plan" a clinically valid statement.

Question 15: A terminally ill patient with Ca pancreas is on IV diamorphine 10 mg/day. The patient is being discharged from the hospital and wishes to convert to oral morphine. What is the approximate oral morphine dose needed for this patient?

A. 20 mg
B. 30 mg (Correct Answer)
C. 40 mg
D. 5 mg

Explanation: ### Explanation The core concept in this question is the **opioid conversion ratio** between parenteral diamorphine and oral morphine. **1. Why Option B (30 mg) is Correct:** In palliative care, converting between different opioids or routes requires specific conversion factors. [1] * **Diamorphine to Morphine:** Diamorphine is approximately **3 times** more potent than oral morphine when given parenterally. * **Calculation:** 10 mg (IV Diamorphine) × 3 = **30 mg (Oral Morphine)**. * *Note:* In the UK and certain palliative guidelines, the standard conversion for Parenteral Diamorphine to Oral Morphine is a ratio of **1:3**. **2. Why Incorrect Options are Wrong:** * **Option A (20 mg):** This assumes a 1:2 ratio. While the IV to Oral ratio for *Morphine* itself is 1:2 or 1:3, Diamorphine is more potent, making 20 mg an under-dose. [1] * **Option C (40 mg):** This assumes a 1:4 ratio, which would over-sedate the patient and increase the risk of respiratory depression. * **Option D (5 mg):** This suggests oral morphine is more potent than IV diamorphine, which is pharmacologically incorrect. Oral medications undergo first-pass metabolism, generally requiring higher doses than parenteral routes. **3. High-Yield Clinical Pearls for NEET-PG:** * **Potency Hierarchy:** Fentanyl > Diamorphine > Morphine > Codeine. * **Morphine IV to Oral Ratio:** Usually **1:2 or 1:3** (e.g., 10 mg IV Morphine ≈ 20–30 mg Oral Morphine). * **Breakthrough Pain:** Always prescribe a "PRN" (as needed) dose for breakthrough pain, typically calculated as **1/6th to 1/10th** of the total 24-hour dose. [1] * **Side Effects:** When starting or increasing doses, always co-prescribe a **stimulant laxative** (e.g., Senna) and an **anti-emetic**, as constipation and nausea are nearly universal side effects.

Question 16: Which of the following is a method of breaking bad news?

A. Burst
B. Spread
C. Spike (Correct Answer)
D. Dive

Explanation: The correct answer is **C. SPIKES**. In palliative care and clinical practice, the **SPIKES protocol** is the gold-standard, six-step strategy designed to assist physicians in delivering bad news (such as a terminal diagnosis or poor prognosis) in a structured, empathetic, and effective manner. Developed by Baile and colleagues, the acronym stands for: * **S – Setting:** Arrange for a private, comfortable environment and involve significant others. * **P – Perception:** Assess what the patient already knows ("Ask before you tell"). * **I – Invitation:** Ask how much information the patient wants to receive [1]. * **K – Knowledge:** Give the information in small chunks, avoiding medical jargon [2]. * **E – Emotions/Empathy:** Address the patient’s emotional reaction with empathetic responses [3]. * **S – Strategy/Summary:** Lay out a clear plan for the next steps and summarize the discussion. **Why other options are incorrect:** * **A, B, and D (Burst, Spread, Dive):** These are not recognized medical protocols or mnemonics for communication skills. They are distractors and do not exist in the context of palliative care or medical ethics. **High-Yield Clinical Pearls for NEET-PG:** * **ABCDE Mnemonic:** Another alternative for breaking bad news (Advance preparation, Build a therapeutic relationship, Communicate well, Deal with patient/family reactions, Encourage emotions). * **NURSE Mnemonic:** Used specifically for responding to emotions (Name, Understand, Respect, Support, Explore). * **The Goal:** The primary aim of SPIKES is to reduce the "psychological impact" on the patient while ensuring they understand the clinical reality to make informed decisions [1].

Question 17: Which of the following is used to measure pain intensity

A. Visual analog scale
B. McGill pain questionnaire
C. Pain behavior checklist
D. Numerical rating scale (Correct Answer)

Explanation: ***Numerical rating scale*** - The **Numerical Rating Scale (NRS)** is a simple, 11-point scale (0-10) where 0 means "no pain" and 10 means "worst possible pain," making it a direct measure of pain intensity. - It is widely used for its **ease of administration** and ability to track changes in pain intensity over time. *Visual analog scale* - The **Visual Analog Scale (VAS)** measures pain intensity using a 10 cm line where patients mark their pain level. While it assesses intensity, the NRS is often preferred for its numerical clarity. - It involves a subjective mark on a line rather than a direct number, which can sometimes be less precise for data collection compared to the NRS. *McGill pain questionnaire* - The **McGill Pain Questionnaire (MPQ)** is a comprehensive tool that assesses not only pain intensity but also the **qualitative and affective dimensions of pain**. - It uses a list of descriptors to characterize pain, providing a more detailed picture of the pain experience rather than just a simple intensity score. *Pain behavior checklist* - A **Pain Behavior Checklist (PBC)** focuses on observable behaviors associated with pain, such as guarding, grimacing, or limping. - It measures the **impact of pain on function and behavior**, not direct pain intensity.

Question 18: What factors should be considered for optimal pain management in a middle-aged patient with metastatic prostate cancer to the bone who is experiencing significant pain?

A. Combination of radiation therapy, chemotherapy, and palliative care consultation (Correct Answer)
B. Surgical intervention as a primary treatment
C. Use of experimental treatments as a first-line option
D. Long-term opioid therapy without additional modalities

Explanation: ***Combination of radiation therapy, chemotherapy, and palliative care consultation*** - **Radiation therapy** is highly effective for localized bone pain due to metastasis, offering significant pain relief by shrinking tumors and reducing bone destruction. - **Chemotherapy** can address systemic disease progression, including various bone metastases, and **palliative care consultation** ensures a holistic approach to pain and symptom management, focusing on quality of life [1]. *Surgical intervention as a primary treatment* - **Surgical intervention** for metastatic bone pain is usually reserved for specific indications like impending **pathological fractures**, **spinal cord compression**, or **stabilization of weight-bearing bones**, rather than being a primary overall pain management strategy [1]. - Surgery carries significant risks and an extended recovery period, which may not align with the goals of comfort and pain relief in a patient with widespread aggressive metastatic disease. *Use of experimental treatments as a first-line option* - **Experimental treatments** are typically considered when standard therapies have failed or for patients enrolling in clinical trials, and they are not a first-line approach for immediate pain management in metastatic cancer. - Their efficacy and safety profiles are often less established than conventional treatments, making them inappropriate as an initial strategy for significant pain. *Long-term opioid therapy without additional modalities* - Relying solely on **long-term opioid therapy** overlooks the multidimensional nature of cancer pain and often leads to inadequate pain control as well as significant side effects like constipation, nausea, and sedation [2]. - This approach fails to address the underlying cause of the pain (tumor growth) and does not utilize other effective pain-reducing modalities such as radiation, which targets the source of the pain directly.

Question 19: According to the Maastricht classification, Category 3 is?

A. dead on arrival to hospital
B. awaiting cardiac arrest after withdrawal of support (Correct Answer)
C. resuscitation attempted without success
D. cardiac arrest while brain dead

Explanation: ***awaiting cardiac arrest after withdrawal of support*** - Under the **Maastricht classification**, Category 3 describes patients who are **expected to die** following the planned withdrawal of life-sustaining treatment. These patients are potential donors after circulatory death (DCD). [1], [2] *dead on arrival to hospital* - This scenario aligns with **Maastricht Category 1** (Uncontrolled DCD), where death occurs outside the hospital setting without prior intervention. - Patients in this category often have unpredictable warm ischemia times, making organ procurement challenging for some organs. *resuscitation attempted without success* - This situation aligns with **Maastricht Category 2** (Uncontrolled DCD), referring to patients declared dead after unsuccessful resuscitation efforts in the emergency department or hospital. - The period of observed death following resuscitation attempts is crucial for determining organ viability. *cardiac arrest while brain dead* - This describes a patient who is **brain dead** but still has some circulatory function, which eventually ceases. This is typically associated with organ donation after brain death (DBD), not the DCD categories defined by Maastricht. [1], [3] - In brain death, the **neurological criteria for death** are met, regardless of circulatory status at the time of diagnosis. [2], [4]

Practice by Chapter

Pain Assessment and Management

Practice Questions

Symptom Control in Advanced Illness

Practice Questions

Communication in Serious Illness

Practice Questions

Advance Care Planning

Practice Questions

Ethical Issues in End-of-Life Care

Practice Questions

Psychosocial Aspects of Palliative Care

Practice Questions

Spiritual Care

Practice Questions

Palliative Care in Non-Cancer Conditions

Practice Questions

Hospice Care

Practice Questions

Family Support and Bereavement

Practice Questions

Palliative Sedation

Practice Questions

Interdisciplinary Team Approach

Practice Questions

Want unlimited practice?

Get full access to all questions, explanations, and performance tracking.

Start For Free